Last reviewed · How we verify
Influenza virus split vaccine
Influenza virus split vaccines contain inactivated influenza viruses that have been disrupted to release viral antigens, which stimulate an immune response against the influenza virus.
Influenza virus split vaccines contain inactivated influenza viruses that have been disrupted to release viral antigens, which stimulate an immune response against the influenza virus. Used for Prevention of influenza caused by virus strains included in the vaccine.
At a glance
| Generic name | Influenza virus split vaccine |
|---|---|
| Sponsor | Jiangsu Province Centers for Disease Control and Prevention |
| Drug class | vaccine |
| Target | Hemagglutinin (HA), Neuraminidase (NA) |
| Modality | Biologic |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
The disruption of the virus particles exposes the internal proteins and hemagglutinin (HA) and neuraminidase (NA) surface glycoproteins, which are key targets for the immune system. This leads to the production of antibodies that can neutralize the virus and prevent infection.
Approved indications
- Prevention of influenza caused by virus strains included in the vaccine
Common side effects
- Injection site pain
- Fatigue
- Headache
Key clinical trials
- High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients (PHASE2)
- A Phase I Trial to Evaluate the Safety and Immunogenicity of Influenza Virus Split Vaccine (Adjuvant) (PHASE1)
- Phase Ⅱ Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above (PHASE2)
- A Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above (PHASE1)
- A Clinical Trial of an Quadrivalent Influenza Virus Subunit Vaccine in Chinese Children Aged 6 to 35 Months (PHASE3)
- Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older (PHASE3)
- High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients (PHASE2)
- Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: